Find Academic Supervisors

Joel GohView profile

Associate Professor

• Health services and systems
• Transportation, logistics and supply chains
• Operations research
• +6 more

Joel Goh is Associate Professor at the Department of Analytics and Operations, NUS Business School, National University of Singapore. He serves as Director of the J.Y. Pillay Comparative Asia Research Centre (under NUS Global Asia Institute) and PhD Program Director at the Institute of Operations Research and Analytics (IORA). Previously, he was Assistant Professor at Harvard Business School (2014-2017) and Visiting Scholar (2017-2022). BSc, MSc, PhD in Operations, Information, and Technology from Stanford University His research focuses on healthcare analytics (preventing health conditions, hospital operations, frailty assessment), supply chain analytics (digital business models, platform leakage), and service platform operations (hospital-at-home programs, incentive design). He co-created the Robust Optimization Made Easy (ROME) software. Recent publications analyze workplace psychological safety (2024), hospital-at-home models (2024), and platform leakage dynamics (2023). His work spans 18+ journals with 740+ citations for burnout cost studies (2022) and 606+ citations for physician well-being research (2017). Teaching Honors : 2023: Best MBA Teaching & Skinner Innovation Award 2021: NUS Annual Teaching Excellence Award 2020: Early Career Research Excellence Award & 40 Under 40 Best MBA Professors Advising & Grants : Served as PhD Program Director. Received NUS Start-Up Grant R-314-000-110-133 (2021) and Humanities & Social Sciences Fellowship (2021). Editorial roles include Associate Editor at Management Science , Manufacturing & Service Operations Management , and Senior Editor at Production and Operations Management .

Benyuan LiuView profile

Professor

• Data and Computer Communication Networks
• Mobile and Wireless Networks
• Internet Technologies & Applications
• +3 more

Benyuan Liu is a Professor at the Miner School of Computer and Information Sciences within the Kennedy College of Sciences at the University of Massachusetts Lowell . He serves as Director and Graduate Coordinator for Ph.D. programs, with expertise in Data and Computer Communication Networks, Mobile and Wireless Networks, and Internet Technologies & Applications. Education: B.S., University of Science and Technology of China M.S., Yale University Ph.D., University of Massachusetts Amherst His research focuses on Artificial Intelligence in Medical Imaging , Deep Learning for Endoscopy , and Edge Computing Systems . Recent work includes automated lesion detection, 3D reconstruction from sensor data, and predictive models for financial and reproductive health domains. The 15 most recent publications highlight applications of deep learning in medical diagnostics (thyroid nodules, gastric lesions, dental caries), computer vision (attention mechanisms, transformers), and financial technology (market psychology analysis). Technical themes include mmwave radar processing, diffusion models for synthetic data, and multi-scale feature extraction. Benyuan Liu leads the Computer Networking Lab and CHORDS initiative at UMass Center for Digital Health. His work bridges network optimization with healthcare AI , emphasizing real-time systems and portable diagnostics.

Brian HieView profile

Assistant Professor

• Machine Learning
• Computational Biology
• Protein Engineering
• +6 more

Brian Hie is an Assistant Professor of Chemical Engineering at Stanford University , a Dieter Schwarz Foundation Stanford Data Science Faculty Fellow , and an Innovation Investigator at Arc Institute . He leads the Laboratory of Evolutionary Design , focusing on the intersection of biology and machine learning . His prior roles include a Stanford Science Fellow in the Stanford University School of Medicine and a Visiting Researcher at Meta AI . Education: Ph.D. , Electrical Engineering and Computer Science , Massachusetts Institute of Technology (2021) Bachelor’s Degree , Stanford University Research Interests: Brian’s work bridges machine learning and computational biology , with a focus on protein engineering , single-cell RNA sequencing , and viral evolution . His Evolutionary velocity framework predicts protein evolutionary dynamics across timescales, while his Scanorama algorithm enables efficient integration of heterogeneous single-cell datasets. He also develops structure-informed language models for antibody optimization and uncertainty-aware ML for biological discovery. Publication Trends: His recent work (2023) emphasizes structure-based inverse folding for antibody evolution, evolutionary scale modeling , and unsupervised optimization . Earlier studies (2022-2021) cover evolutionary velocity , multi-modal single-cell analysis , and viral escape prediction using natural language analogies. Scientific Awards: Stanford Science Fellow (2021) National Defense Science and Engineering Graduate Fellowship (2019) Advising: He mentors doctoral students including Brandon Ameglio , Garyk Brixi , and Chang M. Yun , with a focus on biological design and computational methods . Labs & Collaborations: His lab collaborates with Bio-X and the Institute for Human-Centered Artificial Intelligence (HAI) , and he maintains affiliations with Sarafan ChEM-H and Stanford Data Science .

• Tropical Medicine
• Travel Medicine
• Migrant Health
• +3 more

Sapha Barkati, MD, MSc is an Assistant Professor at the Department of Medicine, Faculty of Medicine and Health Sciences, McGill University , and an Investigator at the RI-MUHC Glen site . Her work bridges clinical practice and research in tropical medicine, focusing on parasitic diseases affecting vulnerable populations. Affiliations: Assistant Professor, McGill University Investigator, Research Institute of the McGill University Health Centre (RI-MUHC) McGill International Tuberculosis Centre Research Focus: Specializes in neglected tropical diseases like strongyloidiasis and tegumentary leishmaniasis, particularly among migrants and immunocompromised individuals. Studies include: Physician awareness of Strongyloides screening Prevalence patterns in non-endemic countries HTLV-1 co-infection treatment response Cost-effective screening strategies Scientific Contributions: Key publications address tropical disease management in non-endemic settings, mpox outbreak dynamics, and SARS-CoV-2 immunity patterns. Her work emphasizes evidence-based guidelines for: Parasite screening in transplant recipients Leishmaniasis treatment protocols Traveler disease prevention Collaborative Networks: Partners with institutions like Universidad Peruana Cayetano Heredia and participates in GeoSentinel surveillance. Leads studies on: Covid-19 health disparities Vaccine effectiveness against variants Remote patient monitoring systems

• Marine Natural Products
• Drug Discovery
• Chemical Ecology
• +4 more

Raymond Andersen is a Professor in the Faculty of Science at the University of British Columbia, affiliated with the Department of Earth, Ocean & Atmospheric Sciences and the Department of Chemistry . His research focuses on the isolation and structural elucidation of bioactive natural products from marine and terrestrial organisms, with applications in drug discovery and chemical ecology. He has contributed to breakthroughs in anticancer agents, antiviral compounds, and inhibitors of Mycobacterium tuberculosis. Education: B.Sc. (University of Alberta, 1969), M.Sc. (Berkeley University, 1970), Ph.D. (University of California San Diego, 1975), followed by postdoctoral training at MIT (1975-76). Awards include the Killam Research Prize (1987), Rutherford Medal in Chemistry (1988), and Fellow of the Chemical Institute of Canada. Research interests span marine invertebrate-derived metabolites, phytoplankton toxins, and plant defensive compounds. His lab investigates antitumor agents, HIV latency reversal, and novel pharmacophores for cancer and infectious diseases. Recent work includes antiviral agents targeting SARS-CoV-2 and inhibitors of androgen receptor signaling in prostate cancer. Co-developed clionamine B, an autophagy-stimulating compound effective against latent tuberculosis. Identified sintokamides as androgen receptor antagonists for prostate cancer therapy. Advanced genome-mining techniques for discovering nonribosomal peptides. Overseen numerous graduate students, including notable theses on natural product synthesis, SAR studies, and bioactivity screening. Active in collaborative drug discovery projects, with patents on androgen receptor modulators, SHIP1 activators, and antiviral agents. Labs/Teams: Leads the Andersen Research Group at UBC, focusing on marine natural products and chemical genetics. Collaborates with the Pacific Museum of Earth and Bamfield Marine Sciences Centre for field studies.

Kyu Y. RheeView profile

Professor

• Tuberculosis
• Antibiotic Resistance
• Metabolomics
• +3 more

Kyu Y. Rhee is a Professor of Medicine and Professor of Microbiology and Immunology at Weill Cornell Medical College . His research focuses on Mycobacterium tuberculosis , with emphasis on metabolic pathways , antibiotic resistance mechanisms , and drug development . Research highlights include: Multi-omic approaches to TB drug discovery Mechanistic studies of antibiotic action Deciphering TB transmission genetics Metabolomics-driven target identification Current funding includes: Bill & Melinda Gates Foundation : AI/ML-assisted bacterial permeability platform National Institute of Allergy & Infectious Diseases : UM1 TB drug regimen design consortium National Heart, Lung, & Blood Institute : Studies on M. tuberculosis PE/PPE proteins and fructose-induced cancer He has authored over 50 publications on TB metabolomics, drug development, and pathogen persistence. His work bridges systems biology , chemical biology , and clinical research to address antimicrobial resistance.

• HIV Infection
• Viral Hepatitis
• Global Health Research
• +5 more

Robert L. Murphy is the John Philip Phair Professor of Infectious Diseases and Professor of Biomedical Engineering at Northwestern University. He directs the Institute for Global Health within the Institute for Public Health and Medicine. His roles include leadership in global health research, infectious disease management, and biomedical engineering. Murphy holds appointments in the Feinberg School of Medicine and McCormick School of Engineering. Education: MD from Loyola University Stritch School of Medicine (1978), Fellowship, Residency, and Board Certification in Internal Medicine at Northwestern University (1981–1984). Research focuses on HIV/AIDS, viral hepatitis, antiviral therapies, and global health disparities. He leads projects in Nigeria, Mali, and other regions, addressing liver fibrosis in HIV/HBV co-infection, cervical cancer in HIV-positive women, and SARS-CoV-2 diagnostics. His work emphasizes point-of-care technologies and epigenetic biomarkers for cancer and liver disease. Publications span over 40 years, with recent emphasis on Omicron variant dynamics, HPV screening in resource-limited settings, and microbiome impacts of antiretroviral therapy. He collaborates globally, co-leading studies on tuberculosis treatment and HIV/drug resistance patterns. Grants and collaborations include the BRAINS faculty development program in Africa, the Test Us Bank (TUB) biorepository for SARS-CoV-2 samples, and partnerships with institutions like the University of Lagos and the Robert H. Lurie Comprehensive Cancer Center.

Andrew de MelloView profile

Professor

• Microfluidics
• Nanotechnology
• Bioanalytical Chemistry
• +5 more

Andrew de Mello serves as Full Professor and Deputy Head at ETH Zurich's Department of Chemistry and Applied Biosciences, where he also leads the Institute of Chemical and Bioengineering. His research group operates at the intersection of microfluidics and nanoscale science, maintaining a highly international team with members from over 15 countries. The deMello Group specializes in microfluidic device development for high-throughput biological analysis, ultrasensitive optical detection , nanofluidic chemical synthesis systems , and imaging flow cytometry . Their work spans analytical chemistry, biomedical engineering, and diagnostic applications, with recent projects focusing on paper-based electrofluidic devices, synthetic gene circuits for tuberculosis detection, and droplet-based microfluidics for mRNA screening. Professor de Mello's scholarly contributions include over 350 peer-reviewed publications and two co-authored books. His editorial leadership includes serving as Associate Editor for ACS Sensors and on editorial boards for Advanced Materials Technologies, Chem, and Chemistry World. Advances in Measurement Science Lectureship (ACS, 2020) Qinghe Lectureship (Chinese Academy of Sciences, 2018) Corday-Morgan Medal (RSC, 2009) Clifford Paterson Medal (Royal Society, 2009) SAC Silver Medal (RSC, 2002) His research group actively mentors doctoral students across diverse projects including microrobot fabrication, tumor spheroid vascularization, and spatial tissue mapping. Current grants support development of diagnostic platforms for kidney function monitoring and drug-resistant tuberculosis detection, with collaborations spanning ETH Zurich, Universitätsspital Zürich, and international institutions.

Martin PrinceView profile

Professor

• Epidemiological Psychiatry
• Global Mental Health
• Dementia Research
• +7 more

Martin Prince is a Professor of Epidemiological Psychiatry at King’s College London, where he serves as Director of the King’s Global Health Institute and Assistant Principal (Global Health) . He is a leading figure in global mental health, with a focus on low- and middle-income countries (LMIC) , dementia, and integrated health systems. His career spans over two decades of coordinating the 10/66 Dementia Research Group and contributing to WHO guidelines, including the mhGAP clinical guidelines and Integrated Care for Older People (ICOPE) . Education: MA, University of Cambridge MD (Epidemiology), University of Cambridge MS (Epidemiology), London School of Hygiene and Tropical Medicine His research bridges mental and physical health , emphasizing task-shifting care to non-specialists in LMIC. Key projects include the NIHR Global Health Research Unit on Health System Strengthening and the ATHLOS project for measuring healthy ageing. His work has informed the UK National Dementia Strategy and WHO’s World Dementia Report . Recent publications highlight depression detection in Ethiopia , dementia risk prediction , and integrated surgical care . He also explores intrinsic capacity and frailty as predictors of dependence and mortality in ageing populations. Scientific Awards: ADI Award (2014) International Psychogeriatric Association Distinguished Service Award (2011) John Mackey Award for Excellence in Dementia Care (2012) Prince leads teams such as the ASSET consortium and HOPE programme on homelessness and severe mental illness in Africa, while advocating for evidence-based policy and equitable healthcare access .

Alessandra LuchiniView profile

Professor

• Nanotechnology
• Proteomics
• Molecular Medicine
• +3 more

Alessandra Luchini serves as Professor in George Mason University's School of Systems Biology and the Center for Applied Proteomics and Molecular Medicine (CAPMM), where she pioneers nanotechnology solutions for cancer and infectious disease diagnostics. Her work bridges biomolecular interface engineering with clinical translation through advanced proteomic platforms. Education Ph.D. from University of Padova, Italy Research Focus : Dr. Luchini's program centers on nanoproteomics for biomarker discovery, specifically developing hydrogel-based affinity capture systems to detect urinary biomarkers of Lyme disease, Chagas disease, and tuberculosis. Her lab innovates in biomimetic membrane models using neutron reflectometry to study pathogen-host interactions, while translating findings into point-of-care diagnostic devices through CAPMM's clinical partnerships. Publication Trends : Recent work (2024-2025) reveals three converging trajectories: (1) urinary peptide diagnostics for tick-borne illnesses validated against clinical symptom scores, (2) engineered nanoparticle networks for pathogen sequestration in blood/plasma, and (3) membrane biophysics studies enabling targeted drug delivery. This integration of basic membrane science with clinical proteomics defines her translational approach. Awards 2023 SCHEV Outstanding Faculty Award for Virginia higher education Research Leadership : As CAPMM principal investigator, Dr. Luchini directs NIH-funded projects developing FDA-cleared diagnostic platforms. Her team collaborates with CDC on Babesia diagnostics and with oncology centers on field cancerization proteomics, while mentoring postdocs in nanoparticle engineering and mass spectrometry techniques. Infrastructure : The CAPMM core facility houses state-of-the-art mass spectrometers, neutron reflectometers, and GMP-compliant nanoparticle synthesis equipment, supporting her lab's work on urinary biomarker validation and affinity capture technology development.

Anders BacklundView profile

Professor

• Pharmacognosy
• Natural Products Chemistry
• Chemical Space Navigation
• +4 more

Anders Backlund is Professor of Pharmacognosy at Uppsala University's Department of Pharmaceutical Biosciences, with dual institutional roles including Garden Director at Uppsala Linnaean Gardens. His work bridges pharmaceutical sciences and botanical heritage through the university's historic gardens. His research centers on pharmacognosy and natural products chemistry, with pioneering development of the ChemGPS-NP platform for chemical space navigation. This computational tool maps biological activity in chemical property space, enabling prediction of pharmacological effects and mechanisms of action. His work spans plant metabolomics, evolutionary chemography, and drug discovery from natural sources including marine organisms, fungi, and medicinal plants. Recent publications (2019-2023) demonstrate strong continuity in applying ChemGPS-NP to diverse problems: predicting membrane permeability of Alpinia galanga constituents (2022), evaluating Ononis isoflavonoids for CNS targeting (2022), and decoding multi-functional bioactivities in Maca (2021). His work increasingly integrates computational prediction with experimental validation across anti-inflammatory, anti-allergic, and antimicrobial domains. As Garden Director of Uppsala Linnaean Gardens, he maintains institutional connections to botanical heritage while advancing modern pharmacognosy. His dual roles exemplify the integration of historical plant knowledge with contemporary drug discovery methodologies.

Lionel PochetView profile

Professor

• Drug Design
• Thrombosis
• Coagulation Cascade
• +3 more

Lionel Pochet is a Professor at the University of Namur, active in drug design, thrombosis research, and analytical chemistry. His work focuses on coagulation cascade inhibitors and fragment-based drug discovery. Namur Medicine & Drug Innovation Center Namur Thrombosis and Hemostasis Center Namur Research Institute for Life Sciences His research spans coumarin derivatives , FXIIa inhibition , and covalent probes for protein interactions. Recent projects include targeted covalent inhibitors for Mycobacterium tuberculosis and lactate dehydrogenase. Key publications highlight pharmacological evaluation , mass spectrometry , and structural chemistry applications in drug discovery. Awards and grants are not explicitly mentioned in the provided text.

Surl-Hee AhnView profile

Assistant Professor

• Molecular Dynamics Simulations
• Enhanced Sampling Methods
• Drug Discovery
• +7 more

Surl-Hee Ahn is an Assistant Professor in the Department of Chemical Engineering at the University of California, Davis. Her research focuses on using molecular dynamics (MD) simulations and enhanced sampling methods like the weighted ensemble (WE) to study biological systems, including proteins, nanocrystals, and drug discovery for tuberculosis and other diseases. She leads the Ahn Lab, which develops cutting-edge computational tools, such as ParGaMD and DeepWEST, to advance kinetic and thermodynamic sampling in simulations. Education: Ph.D. in Chemistry (Chemical Physics), Stanford University M.S. in Chemistry, University of Pennsylvania M.A. in Mathematics, University of Pennsylvania B.A. in Biochemistry and Mathematics, University of Pennsylvania (Magna Cum Laude, Vagelos Scholar) Research Interests: Molecular dynamics simulations, enhanced sampling methods, computational drug discovery, vaccine design, protein interactions, and nanomaterial dynamics. Her work bridges computational biology, materials science, and pharmacology, with applications to infectious diseases and neurodegenerative disorders. Awards and Recognition: 2020 ACM Gordon Bell Prize Winner (SC20) for SARS-CoV-2 spike dynamics simulations 2021 Chancellor’s Outstanding Postdoctoral Scholar Award Finalist MIT Rising Stars in Mechanical Engineering (2018) ACS PHYS Division Young Investigator Award (2021) Grants & Collaborations: Her research is supported by grants from SC20/SC21 and leverages high-performance computing for multiscale modeling. She collaborates on projects like #COVIDisAirborne, combining AI with computational microscopy. Labs & Teams: The Ahn Lab at UC Davis emphasizes interdisciplinary training in computational methods and their application to real-world biomedical challenges.

Marvin MeyersView profile

Professor

• Medicinal Chemistry
• Synthetic Organic Chemistry
• Chemical Biology
• +4 more

Marvin Meyers is a Professor of Chemistry and holds the Kranz Professorship for Excellence in Research at the School of Science and Engineering, Saint Louis University. He leads the Meyers Lab, focused on discovering novel drug candidates for neglected and infectious diseases, particularly antifungals and antiparasitics. His research integrates synthetic organic chemistry, medicinal chemistry, and structure-based drug design to optimize drug candidates' potency, pharmacokinetics, and safety. Educated at Dordt College (B.A., 1996) and the University of Illinois at Urbana-Champaign (Ph.D., 2000), Meyers teaches courses including CHEM 3100, CHEM 3970, and CHEM 4470/5470. His lab emphasizes undergraduate and graduate training in organic synthesis and drug discovery, with students contributing to publications and potential patent applications. Key research interests include drug repurposing (e.g., antifungal phenothiazines), antimalarial agents, and treatments for Cryptosporidium and hepatitis B virus. Collaborations with biologists and computational chemists drive discoveries in molecular pathways and drug targets. The lab's recent work includes antifungal mefloquine analogs (2024), fluorinated triazolopyridazines (2023), and HBV ribonuclease H inhibitors (2021). Meyers' lab is located in Monsanto Hall, and further details are available via www.meyerschemlab.com .

Salmaan A. KeshavjeeView profile

Professor

• Tuberculosis
• Drug-Resistant Tuberculosis
• Global Health Delivery
• +3 more

Salmaan A. Keshavjee, MD, PhD, ScM, serves as Professor of Global Health and Social Medicine at Harvard Medical School and Director of the Center for Global Health Delivery. He concurrently holds appointments as Associate Professor of Medicine at Brigham and Women's Hospital and Faculty Dean of Adams House at Harvard University. His leadership targets critical global health delivery challenges in regions including the Middle East, North Africa, and sub-Saharan Africa through research, training, and policy engagement. Dr. Keshavjee's interdisciplinary foundation combines medical (MD), anthropological (PhD), and public health (ScM) training. This unique background informs his approach to health systems analysis and policy implementation across diverse cultural contexts. As a leading expert in drug-resistant tuberculosis treatment and the anthropology of health policy, his research examines the intersection of infectious disease control, social determinants of health, and structural barriers to care. Additional interests include mental health integration in TB programs, health economics, and digital health applications for disease screening. His fieldwork spans 16 years in Russia, Lesotho, and Pakistan, with extensive collaboration through Partners In Health. Analysis of his recent publications reveals consistent focus on tuberculosis prevention and treatment optimization, with growing attention to mental health comorbidities and artificial intelligence applications. His work addresses diverse populations including prisoners and household contacts across multiple continents, emphasizing regimen feasibility, health system barriers, and economic consequences of inadequate TB control. Key initiatives include the Zero TB Cities project aiming for tuberculosis elimination. Dr. Keshavjee has held influential policy roles including chair of the WHO/Stop TB Partnership’s Green Light Committee for MDR-TB Treatment (2007-2010) and co-authorship of U.S. Institute of Medicine policy papers, though no formal scientific awards are specified in source materials. Through the Center for Global Health Delivery, he mentors fellows in programs such as the Paul Farmer Global Surgery Research Fellowship and Global Mental Health Delivery Fellowship. These initiatives support implementation research in resource-limited settings through structured training and field placements. The Center operates six core programs—Infectious Disease, Mental Health, Noncommunicable Disease, Primary Care, Public Policy, and Surgery—developing evidence-based interventions through partnerships with institutions worldwide. Current priorities include scaling depression screening in TB care, optimizing preventive therapy regimens, and strengthening health systems in the Middle East and North Africa.